High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Dow Jones AI giant Nvidia stock tumbled to a key support level during Tuesday's stock market sell-off. A decisive bounce would be bullish.
AI Stocks are getting hammered on renewed overspending fears. Is this the start of the end?
Eli Lilly (NYSE:LLY) has entered a collaboration and licensing agreement with AlzeCure Pharma for global rights to Alzstatin ACD680, a preclinical Alzheimer's therapy. The deal structure includes potential payments that could exceed US$1b if development, regulatory and commercial milestones are reached. The agreement expands Lilly's neuroscience and Alzheimer's disease pipeline beyond its existing focus on obesity and metabolic treatments. Eli Lilly is best known today for its obesity and...
Eli Lilly (NYSE:LLY) is finally acting like a trillion-dollar drugmaker again. After a brutal stretch in late 2025 and a wobbly start to this year, the stock punched through fresh 52-week highs on retatrutide Phase 3 data that analysts call potentially first-line for obesity. The stock trades at $1,149.15 with a one-year gain of 50.31%, ... Prediction: Eli Lilly Will Trade at This Price in a Year
AlzeCure Deal Expands Lilly's Neuroscience Pipeline Early
AMRX is expanding into GLP-1 manufacturing and biosimilars, using partnerships and acquisitions to strengthen its higher-value product strategy.
LLY stock hits a new all-time high as data from phase III studies show Foundayo outperforming rivals and retatrutide delivering strong weight-loss and diabetes results.
Healthcare ETFs are gaining attention as Middle East tensions and market volatility boost demand for defensive sectors.
For most investors, the race to become the world’s most valuable company feels like a contest between Nvidia (NASDAQ:NVDA) and a handful of AI-first businesses. Yet a growing number of investors are starting to think the biggest AI winner may be a company emerging from industries already possessing something harder to build than a large ... Forget Nvidia and SpaceX. This 150-Year-Old Indiana Company Could Become the World’s Largest in 5 Years
Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
OpenAI confidentially files IPO paperwork, Apple’s AI reveal, Wall Street likes Lilly over Novo in weight-loss wars, and more news to start your day.
Eli Lilly (LLY) shares were up early Tuesday as the drugmaker entered into a collaboration and licen
(Bloomberg) -- The Pentagon accused some of China’s biggest companies, including Alibaba Group Holding Ltd., Baidu Inc. and BYD Co. of supporting the Chinese military, doubling down on an earlier decision to label crown jewels of the country’s corporate world as threats to US national security.Most Read from BloombergHouse Republican Says Hegseth’s D-Day Remarks ‘Inappropriate’LA Mayor Race Flips as Socialist Beats Reality TV Star PrattTrump Says He, Not Congress, Is in Charge of Kennedy Center
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.1% in the afternoon session after the company reported positive Phase 3 data for retatrutide, its next-generation triple-agonist obesity drug.
The pharma giant is well-positioned to lead the $200 billion global obesity treatment market.
Infectious disease could fuel Eli Lilly's next growth phase.
Lilly’s Foundayo outperformed existing treatments on blood sugar control and weight loss in type 2 diabetes patients in three late-stage trials.
Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index shedding 0.4% and
New ATTAIN trial data shows up to 30.4 lbs lost across perimenopause and post-menopause groups
New obesity drug results could strengthen Lilly's lead in weight-loss treatments.
Eli Lilly (LLY) investors have been struggling to answer a deceptively straightforward question for the last two years. How big can the obesity medicine business get? The answer has already helped produce one of the most powerful growth stories in health care. Lilly’s blockbuster drugs Mounjaro and ...
Eli Lilly emerged as the "clear winner" from the ADA meeting last weekend in New Orleans, an analyst said following the event.
Novo's CEO says semaglutide could push the company beyond obesity and diabetes into longevity and appearance-related medicine.
Zealand Pharma's stock is cratering today after disappointing results from a late-stage trial of its GLP-1 dual-receptor agonist drug.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
